N-(3-bromophenyl)-6-methylquinazolin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(3-bromophenyl)-6-methylquinazolin-4-amine
• 化学式: C₁₅H₁₂BrN₃
• 分子量: 314.18
• InChiKey: DBGKBBBQSQCERH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Optical Imaging Contrast Agents
  申请人：Klaveness Jo

  公开号：US20070258904A1

  公开（公告）日：2007-11-08

  The invention provides contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents may be used in diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, for follow up of treatment of oesophageal cancer and Barrett's oesophagus and for surgical guidance. Further, the invention provides methods for optical imaging of oesophageal cancer and Barrett's oesophagus in patients.

  本发明提供用于对患者的食管癌和巴雷特食管进行光学成像的对比剂。这些对比剂可以用于诊断食管癌和巴雷特食管，用于随访疾病发展进程，用于随访食管癌和巴雷特食管的治疗以及用于手术指导。此外，本发明还提供了用于对患者的食管癌和巴雷特食管进行光学成像的方法。
• QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS
  申请人：GPC Biotech AG

  公开号：EP1673346A1

  公开（公告）日：2006-06-28
• Quinazoline derivatives for the treatment of herpesviral infections
  申请人：Herget Thomas

  公开号：US20070123537A1

  公开（公告）日：2007-05-31

  The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.
• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS<br/>[FR] DERIVES DE QUINAZOLINE POUR LE TRAITEMENT D'INFECTIONS VIRALES HERPETIQUES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2005040125A1

  公开（公告）日：2005-05-06

  The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.